12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Phase Ib data

Data from 10 evaluable patients with previously untreated CD20-positive B cell NHL in Part 1 of an open-label, U.S. and French Phase Ib trial showed that once-daily oral ibrutinib plus R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) led to an ORR of 100%, including 7 complete responses and 3 partial responses. DLTs included transient syncope and periorbital cellulitis at the 280 mg dose and gastritis at the 560 mg dose. The most common adverse events were neutropenia, thrombocytopenia, vomiting, anemia, nausea,...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >